Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327327 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Adenocarcinoma, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 9
- Study locations
NCT00327327 is a Phase 1 study of Pancreatic Adenocarcinoma that has completed, run by AmpliMed Corporation. The registered enrollment target is 105 participants, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00327327, a Phase 1 study of Pancreatic Adenocarcinoma, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 9
- Study locations
Study Summary
AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG imexon
Study Locations (9)
Arizona
- Arizona Clinical Research Center - Tucson
Florida
- US Oncology Orlando, Cancer Centers of FL - Ocoee
Indiana
- US Oncology Indiana - Indianapolis
Michigan
- Univ of Michigan - Ann Arbor
New York
- US Oncology Albany, New York Oncology - Albany
Ohio
- US Oncology Kettering - Kettering
Pennsylvania
- Fox Chase Cancer Ctr. - Philadelphia
Virginia
- US Oncology, Virginia Oncology Assoc - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327327
The ClinicalTrials.gov registry entry for NCT00327327 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is AmpliMed Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00327327 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00327327 about?
NCT00327327 is a clinical study titled "Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma". AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1...
What is the current status of trial NCT00327327?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2004-02. Estimated completion is 2009-10.
What conditions does trial NCT00327327 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT00327327?
The interventions under investigation include: gemcitabine (DRUG), imexon (DRUG).
Who is sponsoring clinical trial NCT00327327?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00327327 being conducted?
This trial has 9 study locations across Arizona, Florida, Indiana, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.